BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response
Covered in this story
What has happened since
- Par Technology Corp is up 20.1% since this was published, 13 days ago.
- BillionToOne is up 8.1% since this was published, 13 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $PAR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Par Technology Corp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.